Ключевые слова
Fenotypic features
Stromal Endometriosis
Как цитировать
Аннотация
Endometrial stromal sarcomas are mesenchymal tumors and constitute 0,2-1% of all the malignant uterine pathologies and 6-20% of uterine sarcomas. Commonly they arise in 42-53 year old women. Unlike epithelial tumors, that are having better prognosis, uterine sarcomas are known to have bad prognosis. The recurrence rate and the risk of distant metastasis is high. Local recurrence can be even seen 20-30 years after primary diagnosis and therapy. Radical surgery stands as the primary therapeutic method, often with adjuvant radio- and chemotherapy. Due to the low incidence of endometrial stromal sarcomas, only few things are known about the risk factors of bad outcome and its optimal management.
Библиографические ссылки
Subbaraya, S., Murthy, S. S., & Devi G, S. (2020). Immunohistochemical and
Molecular Characterization of endometrial stromal sarcomas. Clinical Pathology, 13
Hrzenjak A. JAZF1/SUZ12 gene fusion in endometrial stromal sarcomas. Orphanet J Rare Dis. 2016;11:15
Lan, C. , Huang, X. , Lin, S. , Cai, M. , Liu, J. Endometrial stromal sarcoma arising from endometriosis: a clinicopathological study and literature review. Gynecol Obstet Invest. 2012; 74(4): 288–297
Stemme S, Ghaderi M, Carlson JW. Diagnosis of endometrial stromal tumors. Am J Clin Pathol. 2013;141:133-139
Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynecol Obs. 2018;143:51-58
Stemme S, Ghaderi M, Carlson JW. Diagnosis of endometrial stromal tumors: a clinicopathologic study of 25 biopsy specimens with identification of problematic areas. Am J Clin Pathol 2014;141:133–139
Nucci MR. Practical issues related to uterine pathology: endometrial stromal tumors. Mod Pathol. 2016;29 Suppl 1:S92-S103
Albores-Saavedra J, Dorantes-Heredia R, Chable-Montero F et al. Endometrial stromal sarcomas: immunoprofile with emphasis on HMB45 reactivity. Am J Clin Pathol 2014;141:850–855
Sciallis AP, Bedroske PP, Schoolmeester JK et al. Highgrade endometrial stromal sarcomas: a clinicopathologic study of a group of tumors with heterogenous morphologic and genetic features. Am J Surg Pathol 2014;38:1161–1172
Lee CH, Hoang LN, Yip S et al. Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement. Mod Pathol 2014;27:751–757
Shah VI, McCluggage WG. Cyclin D1 does not distinguish YWHAE-NUTM2 high-grade endometrial stromal sarcoma from undifferentiated endometrial carcinoma. Am J Surg Pathol 2015;39:722–724
Gremel G, Liew M, Hamzei F et al. A prognosis based classification of undifferentiated uterine sarcomas: identification of mitotic index, hormone receptors and YWHAE-FAM22 translocation status as predictors of survival. Int J Cancer 2015;136:1608–1618
Perri F, Pisconti S, Della Vittoria Scarpati G. P53 mutations and cancer: a tight linkage. Ann Transl Med. 2016;4(24):522. doi:10.21037/atm.2016.12.40
Roy M, Kumar S, Bhatla N, et al. Androgen Receptor Expression in Endometrial Stromal Sarcoma: Correlation With Clinicopathologic Features. Int J Gynecol Pathol. 2017;36(5):420-427
Przybyl J, Kowalewska M, Quattrone A, et al. Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas. JCI Insight. 2017;2(11):e94033
Yoon JY, de Kock L, Stewart CJR, et al. Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma. Cancer Treat Res Commun. 2021;27:100363
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.